$9.91
0.242.48%
At Close: -
$9.91
00.00%
After Hours: 4:00 PM EDT
15 minutes delayed
Comments
Loading...
AVITA Medical
RCELNASDAQ
Unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
AVITA Medical (NASDAQ:RCEL) Stock, Analyst Ratings, Price Targets, Forecasts
AVITA Medical Inc has a consensus price target of $24.25 based on the ratings of 5 analysts. The high is $40 issued by Lake Street on July 13, 2023. The low is $9 issued by Piper Sandler on May 14, 2024. The 3 most-recent analyst ratings were released by Piper Sandler, Cantor Fitzgerald, and Piper Sandler on May 14, 2024, May 14, 2024, and February 23, 2024, respectively. With an average price target of $17 between Piper Sandler, Cantor Fitzgerald, and Piper Sandler, there's an implied 71.54% upside for AVITA Medical Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Piper Sandler
Cantor Fitzgerald
B of A Securities
Lake Street
1calculated from analyst ratings
Analyst Ratings for AVITA Medical
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 05/14/2024 | Buy Now | -9.18% | Piper Sandler | Matt O'Brien | $21 → $9 | Downgrade | Overweight → Neutral | Get Alert |
| 05/14/2024 | Buy Now | 111.91% | Cantor Fitzgerald | Ross Osborn | $22 → $21 | Maintains | Overweight | Get Alert |
| 04/11/2024 | Buy Now | — | BTIG | Ryan Zimmerman | — | Downgrade | Buy → Neutral | Get Alert |
| 02/23/2024 | Buy Now | 111.91% | Piper Sandler | Matt O'Brien | $19 → $21 | Reiterates | Overweight → Overweight | Get Alert |
| 02/23/2024 | Buy Now | 152.27% | Cantor Fitzgerald | Ross Osborn | $22 → $25 | Maintains | Overweight | Get Alert |
| 01/19/2024 | Buy Now | 122% | Cantor Fitzgerald | Ross Osborn | $20 → $22 | Maintains | Overweight | Get Alert |
| 11/21/2023 | Buy Now | 101.82% | Cantor Fitzgerald | Ross Osborn | → $20 | Reiterates | Overweight → Overweight | Get Alert |
| 11/10/2023 | Buy Now | 91.73% | Piper Sandler | Matt O'Brien | $23 → $19 | Maintains | Overweight | Get Alert |
| 10/19/2023 | Buy Now | 162.36% | Cantor Fitzgerald | Ross Osborn | → $26 | Reiterates | Overweight → Overweight | Get Alert |
| 09/26/2023 | Buy Now | 162.36% | Cantor Fitzgerald | Ross Osborn | → $26 | Reiterates | Overweight → Overweight | Get Alert |
| 08/22/2023 | Buy Now | 162.36% | Cantor Fitzgerald | Ross Osborn | → $26 | Reiterates | Overweight → Overweight | Get Alert |
| 08/11/2023 | Buy Now | 132.09% | Piper Sandler | Matt O'Brien | $18.5 → $23 | Maintains | Overweight | Get Alert |
| 07/28/2023 | Buy Now | 172.45% | B of A Securities | Lyanne Harrison | $18 → $27 | Maintains | Buy | Get Alert |
| 07/13/2023 | Buy Now | 303.63% | Lake Street | Brooks O'Neil | $30 → $40 | Maintains | Buy | Get Alert |
| 06/27/2023 | Buy Now | 132.09% | Cantor Fitzgerald | Ross Osborn | → $23 | Initiates | → Overweight | Get Alert |
| 06/26/2023 | Buy Now | 202.72% | Lake Street | Brooks O'Neil | → $30 | Maintains | Buy | Get Alert |
| 06/09/2023 | Buy Now | 202.72% | Lake Street | Brooks O'Neil | $30 → $30 | Maintains | Buy | Get Alert |
| 05/12/2023 | Buy Now | 202.72% | Lake Street | Brooks O'Neil | $30 → $30 | Maintains | Buy | Get Alert |
| 05/12/2023 | Buy Now | 86.68% | Piper Sandler | Matt O'Brien | $16 → $18.5 | Maintains | Overweight | Get Alert |
| 04/17/2023 | Buy Now | 91.73% | BTIG | Ryan Zimmerman | $16 → $19 | Maintains | Buy | Get Alert |
| 02/24/2023 | Buy Now | 202.72% | Lake Street | Brooks O'Neil | → $30 | Maintains | Buy | Get Alert |
FAQ
What is the target price for AVITA Medical (RCEL) stock?
The latest price target for AVITA Medical (NASDAQ:RCEL) was reported by Piper Sandler on May 14, 2024. The analyst firm set a price target for $9.00 expecting RCEL to fall to within 12 months (a possible -9.18% downside). 13 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for AVITA Medical (RCEL)?
The latest analyst rating for AVITA Medical (NASDAQ:RCEL) was provided by Piper Sandler, and AVITA Medical downgraded their neutral rating.
When was the last upgrade for AVITA Medical (RCEL)?
There is no last upgrade for AVITA Medical
When was the last downgrade for AVITA Medical (RCEL)?
The last downgrade for AVITA Medical Inc happened on May 14, 2024 when Piper Sandler changed their price target from $21 to $9 for AVITA Medical Inc.
When is the next analyst rating going to be posted or updated for AVITA Medical (RCEL)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of AVITA Medical, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for AVITA Medical was filed on May 14, 2024 so you should expect the next rating to be made available sometime around May 14, 2025.
Is the Analyst Rating AVITA Medical (RCEL) correct?
While ratings are subjective and will change, the latest AVITA Medical (RCEL) rating was a downgraded with a price target of $21.00 to $9.00. The current price AVITA Medical (RCEL) is trading at is $9.91, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.